Phase 1/2 clinical study to assess the viability, safety, tolerability and preliminary efficacy of the administration of FAB117-HC, a drug whose active ingredient is HC016, allogenic adult stem mesenchymal cells of expanded adipose tissue pulsed with H2O2, in patients with acute traumatic spinal cord injury
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: FERRER INTERNATIONAL SA
- Phase: II
- Execution start: 05/11/2019
- End of execution: 30/09/2021
- PI: INMACULADA GARCIA MONTES